Risperidone: neurochemical, pharmacologic and clinical properties of a new antipsychotic drug.
Risperidone, a novel antipsychotic with high binding affinity for serotonin 5-HT2 and a lesser affinity for dopamine D2 receptors, is described and clinical studies are reviewed. In two large-scale trials in North America and Europe, risperidone 6 mg and 4 mg to 8 mg/day compared favourably with haloperidol 20 mg or 10 mg/day in controlling the positive symptoms of schizophrenia. In the North American trial, risperidone produced a significant improvement in negative symptoms; no comparable improvement was reported among haloperidol-treated patients. Risperidone would, thus, appear to offer a potential advantage over other neuroleptics, although the place of this new compound in the pharmacological armamentarium of schizophrenia must be clarified in clinical practice.
Keegan
D
D
Department of Psychiatry, University of Saskatchewan, Saskatoon.
D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D001921:Brain / Q000187:drug effects / Q000503:physiopathology; D002986:Clinical Trials as Topic; D006801:Humans; D007555:Isoxazoles / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D010880:Piperidines / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D011569:Psychiatric Status Rating Scales; D017448:Receptors, Dopamine D2 / Q000187:drug effects / Q000502:physiology; D011985:Receptors, Serotonin / Q000187:drug effects / Q000502:physiology; D018967:Risperidone; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology; D012565:Schizophrenic Psychology
D014150:Antipsychotic Agents; D007555:Isoxazoles; D010880:Piperidines; D017448:Receptors, Dopamine D2; D011985:Receptors, Serotonin; D018967:Risperidone